[Management of patients with Duchenne muscular dystrophy]

Tadayuki Ishihara1

  • 1Department of Neurology, National Hokone Hospital, Odawara, Kanagawa. isiharat@hakone.hosp.go.jp

Insights

Management of cardiopulmonary complications in Duchenne muscular dystrophy (DMD) has improved survival. Advances in respiratory support, like NIPPV, have significantly extended lives, offering hope for better outcomes.

Area of Science:

  • Neurology
  • Cardiology
  • Pulmonology

Context:

  • Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder with no cure.
  • Cardiopulmonary complications are the primary cause of mortality in DMD patients.
  • Historically, survival was limited, with respiratory failure and heart failure being major concerns.

Purpose:

  • To review the evolution of managing cardiopulmonary complications in Duchenne muscular dystrophy.
  • To highlight advancements in respiratory support and their impact on patient survival.
  • To discuss the role of brain natriuretic peptide (BNP) in managing left-sided heart failure in DMD.

Summary:

  • Respiratory failure was the leading cause of death in DMD patients in 1984.
  • Introduction of cuirass ventilation and later Non-Invasive Positive Pressure Ventilation (NIPPV) significantly prolonged survival.
  • Brain natriuretic peptide (BNP) is a valuable marker for assessing left ventricular function and guiding treatment for heart failure in DMD.

Impact:

  • Improved management strategies have increased the average age of death for DMD patients.
  • Non-Invasive Positive Pressure Ventilation (NIPPV) has extended survival by approximately 5.5 years.
  • Continued research is crucial for developing a cure for Duchenne muscular dystrophy.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...